Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab

被引：0
作者：
Van Asten, K. [1 ]
Jongen, L. [1 ]
Beuselinck, B. [2 ]
Laenen, A. [3 ]
Wildiers, H. [2 ]
Poppe, A. [4 ]
Floriss, G. [5 ]
Christiaens, M. [6 ]
Neven, P. [4 ]
机构：
[1] Katholieke Univ Leuven, Oncol, Leuven, Belgium
[2] UZ Leuven, Gen Med Oncol, Leuven, Belgium
[3] Katholieke Univ Leuven, Interuniv Ctr Biostat & Stat Bioinformat, Leuven, Belgium
[4] UZ Leuven, Gynaecol & Obstet, Leuven, Belgium
[5] UZ Leuven, Imaging & Pathol, Leuven, Belgium
[6] UZ Leuven, Surg, Leuven, Belgium
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P270
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [41] Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells
    Mao, Yan
    Zhang, Yuzi
    Qu, Qing
    Zhao, Meizhong
    Lou, Ying
    Liu, Junjun
    Huang, Ou
    Chen, Xiaosong
    Wu, Jiayi
    Shen, Kunwei
    [J]. MOLECULAR BIOSYSTEMS, 2015, 11 (04) : 1029 - 1040
  • [42] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
    Vaidya, T. R.
    Ait-Oudhia, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
  • [43] Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab
    Debska-Szmich, S.
    Kusinska, R.
    Krakowska, M.
    Czyzykowski, R.
    Czernek, U.
    Zadrozna, A.
    Potemski, P.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [44] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    [J]. BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [45] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [46] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    [J]. BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [47] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina Diaz, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Paz Santiago, Maria
    Concha, Angel
    Eva Perez, Maria
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer
    Nafi, S. Mohd
    Kong, A.
    Gijsen, M.
    Kramer-Marek, G.
    Capala, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 126 - 126
  • [49] Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer
    Lion, Maeva
    Harle, Alexandre
    Salleron, Julia
    Ramacci, Carole
    Campone, Mario
    Merlin, Jean-Louis
    [J]. ONCOLOGY LETTERS, 2016, 12 (03) : 2028 - 2032
  • [50] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    [J]. Breast Cancer, 2015, 22 : 292 - 299
12345